2-imidazo[1,2-a]pyridin-3-ylacetic acid

We are 2-imidazo[1,2-a]pyridin-3-ylacetic acid CAS:17745-04-9 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:2-imidazo[1,2-a]pyridin-3-ylacetic acid
CAS.NO:17745-04-9
Synonyms:2-imidazo[1,2-a]pyridin-3-ylacetic acid
Imidazo(1,2-a)pyridine-3-acetic acid
imidazo<1,2-a>pyridin-3-acetic acid
(imidazo[1,2-a]pyridine-3-yl)ethanoic acid
2-(imidazo[1,2-a]pyridin-3-yl)acetic acid
imidazo[1,2-a]pyridin-3-ylacetic acid
 
Physical and Chemical Properties:
Density 1.4±0.1 g/cm3
Molecular Formula C9H8N2O2
Molecular Weight 176.172
 
Specification:
Appearance:Light yellow to brown powder
Assay:≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Minodronic Acid(CAS:180064-38-4).

2-imidazo[1,2-a]pyridin-3-ylacetic acid


Related News: Featured APIs: Production capacity continues to expand, targeted patents expire. Original research drugs: industry entry barriers are high, performance stability and certainty are high.99-04-7 Due to the cyclic nature of the upstream chemical products of the API, it is expected that the impact of price fluctuations of raw materials on the performance of API companies is unavoidable, but companies with thick product lines and the ability to produce intermediates are expected to minimize the upstream price impact.85070-48-0 Optimize the reaction and improve the production process to reduce the production cost. At the same time, strengthen the determination and analysis of impurities to improve product quality.3-cloro-4-fluorobenzotrifluoruro CAS:78068-85-6 Optimize the reaction and improve the production process to reduce the production cost. At the same time, strengthen the determination and analysis of impurities to improve product quality.Onconova is currently in the clinical development stage with oral and IV rigosertib, including clinical trials studying single agent IV rigosertib in second-line higher-risk MDS patients (pivotal Phase 3 INSPIRE trial) and oral rigosertib plus azacitidine in first-line and refractory higher-risk MDS patients (Phase 2).

Related Products
Product Name
2-Amino-6-fluorobenzonitrile View Details
4-(1-Acetylpiperazin-4-yl)Phenol View Details
perfluorooctane Cas:307-34-6 View Details
2,4-Difluorobenzyl Chloride manufacturer 4-[(4-fluoroanilino)methylidene]cyclohexa-2,5-dien-1-one manufacturer 4-Nitrobenzyl Chloroformate manufacturer 3-[4-[2-[4-(2,3-dichlorophenyl)piperazin-1-yl]ethyl]cyclohexyl]-1,1-dimethylurea,hydrochloride manufacturer 2,3-Dibromopropionic acid manufacturer